生物学的薬による炎症性腸疾患の患者における標準対強化型肺炎球菌ワクチン接種の比較:将来性,多センター,ランダム化,オープンラベル試験
Xavier Roblin1,2,3,4, Sophie Vieujean5,6, Stéphane Nancey7
1Department of Gastroenterology, Saint-Etienne University Hospital, Saint-Etienne, France.
Journal of Crohn's & colitis
|August 25, 2025
まとめ
肺炎球菌ワクチン接種スケジュールは,生物学的治療を受けている炎症性腸疾患 (IBD) の患者の免疫反応を著しく改善します. この改善された反応は36ヶ月間持続し,IBD患者にとってよりよい保護を提供します.
科学分野:
- 免疫学
- 胃腸内科
- ワクチン学
背景:
- 炎症性腸疾患 (IBD) の患者にとって,肺炎球菌ワクチン接種は極めて重要です.
- 肺炎球菌ワクチンの有効性は,抗腫瘍死滅因子 (TNF) または免疫抑制療法を受けているIBD患者において低下しています.
- ベドリズマブは,潜在的に異なる免疫調節効果を持つ代替生物学的治療法を提供します.
研究 の 目的:
- 抗TNF (免疫抑制剤と併用) またはヴェドリズマブによる治療を受けたIBD患者における標準対強化型肺炎球菌ワクチン接種戦略の免疫原性を比較する.
- 36ヶ月間にわたって異なるワクチン接種方式の持続免疫応答と安全性プロフィールを評価する.
主な方法:
- 生物療法による臨床寛解のIBD患者104人を対象とした前向きな多センターランダム化オープンラベル研究.
- 患者は,濃縮型 (PCV13/ PCV13/ PPSV23) または標準型 (PCV13/ PPSV23) の肺炎球菌ワクチン接種にランダムに割り当てられました.
- 免疫反応は,ELISAとオプソナファゴシタ検査 (OPA) を用いて,最大36ヶ月までの様々な時間点で評価された.
主要な成果:
- 強化されたワクチン接種は,ELISAとOPAの両方で測定された標準療法と比較して,5ヶ月で有意に高いワクチン反応率をもたらしました.
- 12, 18, 36ヶ月の集中治療群では,継続的に高いOPA反応が観察されました.
- ワクチンの反応の減少は,抗TNF療法,結合免疫抑制療法,およびクローン病と関連していたが,両方の治療法は安全性またはIBD再発率の有意な差異なく良好に耐えた.
結論:
- 強化型肺炎球菌ワクチン接種は,IBD患者の免疫反応を36ヶ月間にわたって大幅に強化し維持します.
- この強化されたアプローチは,特に抗TNF治療を受けているクローン病の患者にとって有益です.
- 標準ワクチンと強化ワクチン接種は,好ましい安全性プロファイルを示し,IBD再発率を増加させなかった.
関連する概念動画
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Inflammatory Bowel Disease II: Crohn's Disease
382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202


